Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
White Water Rafting Turkey
Popular Articles
Stretch Mark

National Organization for Rare Disorders (NORD) Sponsors Rare Disease Summit
A shortage of new pharmaceutical products in the pipeline-combined with new scientific tools-has created a climate of opportunity for the rare disease community, a senior Food and Drug Administration (FDA) official said at a conference hosted by the National Organization for Rare Disorders (NORD).
generic viagra online
Suspect In Murder Of Abortion Provider Tiller Sends Antiabortion Mailings From Jail
From his jail cell, Scott Roeder, the man charged in the murder of abortion provider George Tiller, has been sending inflammatory pamphlets calling such killings justifiable and corresponding with radical antiabortion-rights groups, the AP/Boston Globe reports. The pamphlets call Paul Hill, who was convicted of murdering abortion provider John Bayard Britton and his bodyguard in 1994, an "American hero" and quotes some of Hill"s writing about how murdering abortion providers is acceptable. Roeder obtained the pamphlets from the antiabortion-rights group Army of God. Roeder also has been corresponding with the Rev. Donald Spitz, founder of Army of God, and antiabortion-rights advocate Linda Wolfe, who has been jailed about 50 times for antiabortion activities and is a close friend of the woman convicted of shooting Tiller in the arms in 1993. The AP/Globe reports that the FBI and Department of Justice declined to comment on whether they are concerned about Roeder"s mailings. Last month, Roeder in an interview said that there are "many other similar events planned around the country as long as abortion remains legal." Roeder has not been accused of breaking any laws because of the correspondence (AP/Boston Globe, 7/4).
News of the day
Young Adults Face Tough Time Getting Insurance
Young adults are facing tough times with limited job prospects and no health insurance. The Associated Press reports on recent college graduate Emily Weinstein as being representative of the many young uninsured Americans: "Like millions of other uninsured adults in their 20s, Weinstein is watching Congress as it advances legislation to overhaul health care. The recession has deepened young adults" career struggles. It has also sharpened their interest in health insurance. Already the least likely of any age group to have coverage, adults in their 20s face brutal job searches and more time uninsured because of the recession. Nearly 30 percent, 13.2 million, were uninsured in 2007, according to the Commonwealth Fund, a New York-based research center. Many young adults work entry-level jobs without insurance and, despite new laws in some states, they"re eventually too old to stay on their parents" policies."
Nutrition

CeNeRx BioPharma Obtains Rights To Novel Drug Candidate For Prevention And Treatment Of Neurodegeneration Disorders

CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), announced that it has obtained the rights to develop and market a novel agent for the prevention and treatment of neuropathies and neurodegenerative disorders. The drug candidate, CXB909, is a small molecule, orally active agent that enhances the effects of nerve growth factor (NGF). CeNeRx intends to initiate a Phase l trial of CXB909 for the treatment of chemotherapy-induced peripheral neuropathy (CIPN) later this year. "Nerve growth factor has long been of interest as a potential therapy for neuropathies and neurodegenerative diseases, but recombinant NGF lacks key qualities needed for successful CNS drugs," said Dr. Daniel Burch, Executive Vice President of R&D and Chief Medical Officer of CeNeRx. "In preclinical studies, our small molecule agent CXB909 has been shown to increase the action of native NGF, but without the pharmacokinetic and administration challenges of recombinant NGF. Most notably, CXB909 crosses the blood brain barrier, has a long half-life and is orally available. The preclinical data for this agent is very promising, and we look forward to assessing it in the clinic for neuropathic and neurodegenerative conditions that currently have no treatment options." CXB909 is a downstream enhancer of the effects of nerve growth factor, an endogenously produced neurotrophic factor that is important for the function and survival of several types of neurons. Both Alzheimer"s disease and Huntington"s disease involve the degeneration of certain neurons, and neuronal damage is also implicated in the peripheral neuropathies associated with diabetes, kidney disease, cancer chemotherapy and other conditions. In preclinical studies, CXB909 enhanced the action of NGF in vitro, amplifying its activity almost seven-fold. CXB909 was neuroprotective in a variety of cellular assays and in animal models of neuropathies and neurodegenerative diseases, including chemotherapy-induced neuropathy, for which there is currently no approved treatment. "The addition of CXB909 to our development pipeline is another example of the growing success of our strategy to in-license novel CNS agents with validated mechanisms for the treatment of underserved CNS disorders," said Barry Brand, Chief Executive Officer of CeNeRx. "Our rapidly aging population is at risk for devastating neuropathic and neurodegenerative diseases that lack effective therapies. We intend to move quickly to test CXB909 in relevant conditions, beginning with chemotherapy-induced peripheral neuropathy, a disabling and dose-limiting side effect of cancer treatment with a relatively straightforward pathway to clinical development and regulatory review." CXB909 was licensed from Krenitsky Pharmaceuticals Inc., which also licensed the RIMA series of selective and reversible monoamine oxidase inhibitor (MAOI) compounds to CeNeRx. The lead compound in that program, TriRima(TM), is currently in a Phase II trial for the treatment of major depressive disorder. Further details of the new licensing agreement were not disclosed. About CeNeRx BioPharma CeNeRx is a privately held clinical stage biopharmaceutical company developing and commercializing innovative treatments for diseases of the central nervous system. CeNeRx"s most advanced compound, a reversible inhibitor of monoamine oxidase, or RIMA, is in Phase II development for the treatment of major depressive disorder. RIMAs may have efficacy advantages over current agents for depression and are expected to have a good safety profile. The company"s CNS pipeline also includes CXB909, a small molecule, orally active agent for the prevention and treatment of neuropathies and neurodegenerative disorders; a series of novel compounds for anxiety and depression; and a series of selective cannabinoid compounds that have recently completed successful preclinical proof-of-concept studies for the treatment of pain, glaucoma and spasticity. CeNeRx BioPharma, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009